Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2023-04-24 Major Shareholding Noti…
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 2674X' and contains the standard footer information referencing 'RNS, the news service of the London Stock Exchange' and the FCA. The content itself is a 'TR-1: Standard form for notification of major holdings' detailing an acquisition/disposal of voting rights by BlackRock, Inc. This type of mandatory disclosure regarding changes in significant share ownership thresholds falls directly under the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-04-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and details an acquisition/disposal of voting rights by BlackRock, Inc. in Syncona Limited. It includes specific fields for reporting changes in share ownership thresholds (e.g., Resulting situation on the date on which threshold was crossed or reached shows 10.020000% total holding). This structure is characteristic of regulatory filings related to significant shareholder changes. The presence of 'RNS Number' and the footer mentioning RNS, the London Stock Exchange, and the Financial Conduct Authority confirms it is a regulatory announcement. This type of filing, reporting changes in major shareholdings, aligns best with the definition for Major Shareholding Notification (MRQ).
2023-04-19 English
Freeline reports Full Year 2022 Financial Results
Earnings Release Classification · 95% confidence The document is a press release issued by Syncona Limited regarding its portfolio company, Freeline Therapeutics Holdings plc. It provides a summary of Freeline's full-year 2022 financial results, corporate restructuring, and strategic updates. While it contains financial highlights, it is an initial announcement (Earnings Release) rather than the full audited annual report. It follows the standard format of an earnings press release, including key highlights, management commentary, and forward-looking statements. FY 2022
2023-04-04 English
Syncona expands portfolio with £22.5m Series A
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated '04 April 2023'. The content describes Syncona Limited's commitment to a Series A financing round for a new portfolio company, Mosaic Therapeutics. This is a corporate action announcement regarding investment and portfolio expansion, which falls under financing activities. Since it is a formal announcement distributed via RNS (London Stock Exchange's news service), it is a regulatory announcement. However, the specific nature of the announcement—a capital commitment/financing deal—aligns best with the 'Capital/Financing Update' (CAP) category. It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). While it is distributed via RNS, the specific content points strongly to CAP.
2023-04-04 English
Update re. Silicon Valley Bank
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7196S' and is dated March 13, 2023. It provides an 'Update re. Silicon Valley Bank' concerning the company's exposure and next steps, concluding with an 'Enquiries' section and a footer explicitly stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a regulatory news service announcement. Since the content is a specific, timely update that doesn't fit the definitions for ER, IR, CAP, or LTR, and it is clearly an announcement rather than a full report (like 10-K or AR), the most appropriate classification is the general regulatory announcement category, RNS.
2023-03-13 English
Achilles reports Q4 and full year 2022 Results
Earnings Release Classification · 100% confidence The document is a press release issued by Syncona Limited regarding its portfolio company, Achilles Therapeutics Plc. It provides a summary of Achilles' financial results for the fourth quarter and full year 2022, including key highlights, business updates, and consolidated balance sheets. Since this is the initial announcement of financial results containing key highlights and financial data, it is classified as an Earnings Release (ER). FY 2022
2023-03-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.